The utility of procalcitonin in critically ill trauma patients

Journal of Trauma and Acute Care Surgery

Volumn 73, Issue 2, 2012, Pages 413-418

  Sakran, Joseph V ^a,b,c   Michetti, Christopher P ^a   Sheridan, Michael J ^a,b   Richmond, Robyn ^a   Waked, Tarek ^a   Aldaghlas, Tayseer ^a,d   Rizzo, Anne ^a   Griffen, Margaret ^a   Fakhry, Samir M ^a,e  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Inova Research Center   (United States)

^c Trauma Center at Penn   (United States)

^d HOSPITAL OF SAINT RAPHAEL   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

biomarker; intensive care unit; Procalcitonin; sepsis; trauma

Indexed keywords

PROCALCITONIN;

ADULT; ARTICLE; BLOODSTREAM INFECTION; BLUNT TRAUMA; CLINICAL ASSESSMENT; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; FEMALE; HOSPITAL; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INJURY SCALE; INJURY SEVERITY; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; APACHE; BIOLOGICAL MARKERS; CALCITONIN; COHORT STUDIES; CONFIDENCE INTERVALS; CRITICAL CARE; CRITICAL ILLNESS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HOSPITAL MORTALITY; HUMANS; INJURY SEVERITY SCORE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEPSIS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRAUMA CENTERS; WOUNDS, NONPENETRATING;

EID: 84864623943     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e31825ff5b7     Document Type: Article

References (40)

1. Mann EA, Baun MM, Meininger JC, Wade CE. Comparison of mortality associated with sepsis in the burn, trauma, and general intensive care unit patient: A systematic review of the literature. Shock. 2011.
2. Kim MH, Lim G, Kang SY, et al. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei Med J. 2011;52:276Y281.
3. Mitaka C. Clinical laboratory differentiation of infectious versus noninfectious systemic inflammatory response syndrome. Clin Chim Acta. 2005;351:17Y29.
4. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med. 1993;328:1471Y1477.
5. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589Y1596.
6. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296Y327.
7. Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: A review. Pathology. 2007;39:383Y390.
8. Clyne B, Olshaker JS. The C-reactive protein. J Emerg Med. 1999;17:1019Y1025.
9. Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341:515Y518.
10. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis. Crit Care Med. 2006;34:1996Y2003.
11. Ventetuolo CE, Levy MM. Biomarkers: diagnosis and risk assessment in sepsis. Clin Chest Med. 2008;29:591Y603.
12. Weglohner W, Struck J, f ischer-Schulz C, et al. Isolation and characterization of serum procalcitonin from patients with sepsis. Peptides. 2001;22:2099Y2103.
13. Jacobs JW, Lund PK, Potts JT Jr, et al. Procalcitonin is a glycoprotein. J Biol Chem. 1981;256:2803Y2807.
14. Meisner M, Muller V, Khakpour Z, et al. Induction of procalcitonin and proinflammatory cytokines in an anhepatic baboon endotoxin shock model. Shock. 2003;19:187Y190.
15. Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-1 gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86:396Y404.
16. Morgenthaler NG, Struck J, Fischer-Schulz C, et al. Detection of procalcitonin (PCT) in healthy controls and patients with local infection by a sensitive ILMA. Clin Lab. 2002;48:263Y270.
17. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med. 2001;164:396Y402.
18. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med. 2000;28:977Y983.
19. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R. Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med. 2000;26(Suppl 2):S148YS152.
20. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31:1737Y1741.
21. Endo S, Aikawa N, Fujishima S, Sekine I, Kogawa K, Yamamoto Y, et al. Usefulness of procalcitonin serum level for the discrimination of severe sepsis from sepsis: A multicenter prospective study. J Infect Chemother. 2008;14:244Y249.
22. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment of antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600Y607.
23. Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med. 2008;34:1434Y1440.
24. Mongardon N, Lemiale V, Perbet S, et al. Value of procalcitonin for diagnosis of early onset pneumonia in hypothermia-treated cardiac arrest patients. Intensive Care Med. 2010;36:92Y99.
25. Jensen J, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: A randomized trial. Crit Care Med. 2011;39:2048Y2058.
26. Becker K, Snider R, Nylen E. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36:941Y952.
27. Wanner GA, Keel M, Steckholzer U, et al. Relationship between procalcitonin plasma levels and severity of injury, sepsis, organ failure, and mortality in injured patients. Crit Care Med. 2000;28:950Y957.
28. MeisnerM, Adina H, Schmidt J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. Crit Care. 2006;10:R1.
29. Oconnor E, Venkatesh B, Mashongonyika C, et al. Serum procalcitonin and C-reactive protein as markers of sepsis and outcome in patients with neurotrauma and subarachnoid haemorrhage. Anaesth Intensive Care. 2004;32:465Y470.
30. Hensler T, Sauerland S, Lefering R, et al. The clinical value of procalcitonin and neopterin in predicting sepsis and organ failure after major trauma. Shock. 2003;20:420Y426.
31. Castelli GP, Pognani C, Meisner M, et al. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care Med. 2004;R234YR242.
32. Castelli GP, Pognani C, Cita M, et al. Procalcitonin as a prognostic and diagnostic tool for septic complications after major trauma. Crit Care Med. 2009;37:1845Y1849.
33. Haasper C, Kalmbach M, Dikos GD, et al. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. Technol Health Care. 2010;18:89Y100.
34. Christ-Crain, M, Stolz, D, Bingisser, R, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med. 2006;174:84Y93.
35. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303Y1310.
36. Selassie AW, Fakhry SM, Ford D. Population-based study of the risk of inhospital death after traumatic brain injury:The role of sepsis. J Trauma. 2011;71:1226Y1234.
37. ACCP-SCCM Consensus Conference. Definitions of sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864Y874.
38. Chan YL, Tseng CP, Tsay PK, et al. Procalcitonin as a marker of bacterial infection in the emergency department: An observational study. Crit Care Med. 2005;33:894Y895.
39. Jensen JU, Heslet L, Jensen TH, et al. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med. 2006;24:2596Y2602.
40. Kopterides P, Siempos II, Tsangaris I, et al. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: A systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2010;38:2229Y2241.